These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15741224)

  • 1. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
    McLaughlin P; Estey E; Glassman A; Romaguera J; Samaniego F; Ayala A; Hayes K; Maddox AM; Preti HA; Hagemeister FB
    Blood; 2005 Jun; 105(12):4573-5. PubMed ID: 15741224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.
    Nastoupil LJ; McLaughlin P; Feng L; Neelapu SS; Samaniego F; Hagemeister FB; Ayala A; Romaguera JE; Goy AH; Neal E; Wang M; Fayad L; Fanale MA; Oki Y; Westin JR; Rodriguez MA; Cabanillas F; Fowler NH
    Br J Haematol; 2017 Apr; 177(2):263-270. PubMed ID: 28340281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
    McLaughlin P; Hagemeister FB; Rodriguez MA; Sarris AH; Pate O; Younes A; Lee MS; Dang NH; Romaguera JE; Preti AH; McAda N; Cabanillas F
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):37-41. PubMed ID: 11225999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
    Sarris AH; Jiang Y; Tsimberidou AM; Thomaides A; Rassidakis GZ; Ford RJ; Medeiros LJ; Cabanillas F; McLaughlin P
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):48-55. PubMed ID: 11842389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
    Tsimberidou AM; McLaughlin P; Younes A; Rodriguez MA; Hagemeister FB; Sarris A; Romaguera J; Hess M; Smith TL; Yang Y; Ayala A; Preti A; Lee MS; Cabanillas F
    Blood; 2002 Dec; 100(13):4351-7. PubMed ID: 12393618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
    Au WY; Chan LC; Liang R; Kwong YL
    Am J Hematol; 2006 Jun; 81(6):471-3. PubMed ID: 16680740
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of mitoxantrone in the treatment of indolent lymphomas.
    Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
    Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
    Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
    Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
    Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients.
    Ma SY; Au WY; Chim CS; Lie AK; Lam CC; Tse E; Leung AY; Liang R; Kwong YL
    Br J Haematol; 2004 Mar; 124(6):754-61. PubMed ID: 15009063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.
    Vitolo U; Ladetto M; Boccomini C; Baldini L; De Angelis F; Tucci A; Botto B; Chiappella A; Chiarenza A; Pinto A; De Renzo A; Zaja F; Castellino C; Bari A; Alvarez De Celis I; Evangelista A; Parvis G; Gamba E; Lobetti-Bodoni C; Ciccone G; Rossi G
    J Clin Oncol; 2013 Sep; 31(27):3351-9. PubMed ID: 23960180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.
    Tsimberidou AM; Younes A; Romaguera J; Hagemeister FB; Rodriguez MA; Feng L; Ayala A; Smith TL; Cabanillas F; McLaughlin P
    Cancer; 2005 Jul; 104(2):345-53. PubMed ID: 15948158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy.
    Coso D; Costello R; Cohen-Valensi R; Sainty D; Nezri M; Gastaut JA; Bouabdallah R
    Ann Oncol; 1999 Mar; 10(3):362-3. PubMed ID: 10355587
    [No Abstract]   [Full Text] [Related]  

  • 14. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.
    McLaughlin P; Hagemeister FB; Romaguera JE; Sarris AH; Pate O; Younes A; Swan F; Keating M; Cabanillas F
    J Clin Oncol; 1996 Apr; 14(4):1262-8. PubMed ID: 8648382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.
    Carney DA; Westerman DA; Tam CS; Milner A; Prince HM; Kenealy M; Wolf M; Januszewicz EH; Ritchie D; Came N; Seymour JF
    Leukemia; 2010 Dec; 24(12):2056-62. PubMed ID: 20962860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
    Zinzani PL; Pellegrini C; Broccoli A; Gandolfi L; Stefoni V; Casadei B; Maglie R; Argnani L; Pileri S
    Hematol Oncol; 2015 Sep; 33(3):141-6. PubMed ID: 24986783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
    Seiter K; Feldman EJ; Sreekantaiah C; Pozzuoli M; Weisberger J; Liu D; Papageorgio C; Weiss M; Kancherla R; Ahmed T
    Leukemia; 2001 Jun; 15(6):963-70. PubMed ID: 11417484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experience with fludarabine treatment and review of the literature].
    Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
    Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years.
    Casadei B; Pellegrini C; Pulsoni A; Annechini G; De Renzo A; Stefoni V; Broccoli A; Gandolfi L; Quirini F; Tonialini L; Morigi A; Argnani L; Zinzani PL
    Cancer Med; 2016 Jun; 5(6):1093-7. PubMed ID: 26990782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy.
    Scaramucci L; Niscola P; Buffolino S; Bongarzoni V; Cimino G; Montanaro M
    Hematol J; 2004; 5(2):186-7. PubMed ID: 15048071
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.